Russell Investments Group
LUCD icon

Russell Investments Group’s Lucid Diagnostics LUCD Stock Holding History

Russell Investments Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
1,651,788
+68,180
+4% +$73.5K ﹤0.01% 2154
2026
Q1 		$1.82M Buy
1,583,608
+1,573,481
+15,537% +$2M ﹤0.01% 1925
2025
Q4 		$11K Buy
10,127
+2,200
+28% +$2.46K ﹤0.01% 3774
2025
Q3 		$8.01K Buy
+7,927
New +$8.66K ﹤0.01% 3828

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Russell Investments Group's LUCD Position: Q2 2026 in Review

Russell Investments Group increased its Lucid Diagnostics (LUCD) stake by 4.3% in Q2 2026, buying an estimated $73.5K and bringing the position to 1,651,788 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Russell Investments Group first reported a position in LUCD in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.82M in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Russell Investments Group held 1,651,788 shares of Lucid Diagnostics worth $1.77M as of Q2 2026.
  • Russell Investments Group bought 68,180 Lucid Diagnostics shares in Q2 2026, an estimated $73.5K.
  • Lucid Diagnostics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2154 holding.
  • Russell Investments Group first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • Russell Investments Group's Lucid Diagnostics position peaked at $1.82M in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.